| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6130208 | CHIESI | Formulation containing a nucleotide analogue |
Jun, 2023
(2 months ago) | |
| US9925265 | CHIESI | Methods of treating or preventing stent thrombosis |
May, 2029
(5 years from now) | |
| US9427448 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Nov, 2030
(7 years from now) | |
| US8680052 | CHIESI | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
Mar, 2033
(9 years from now) | |
| US9439921 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US9295687 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US9700575 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
| US10039780 | CHIESI | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
Jul, 2035
(11 years from now) | |
Kengreal is owned by Chiesi.
Kengreal contains Cangrelor.
Kengreal has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Kengreal are:
- US6130208
Kengreal was authorised for market use on 22 June, 2015.
Kengreal is available in powder;intravenous dosage forms.
Kengreal can be used as method of reducing the risk of periprocedural myocardial infarction, and stent thrombosis in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and then a continuous infusion, p2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor, method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci, method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method.
The generics of Kengreal are possible to be released after 10 July, 2035.
Drugs and Companies using CANGRELOR ingredient
Market Authorisation Date: 22 June, 2015
Treatment: P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a ...
Dosage: POWDER;INTRAVENOUS
KENGREAL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic